Company Tied to Amgen Gains Patent on Protein
- Share via
Regeneron Pharmaceuticals Inc. said it has been awarded a patent covering the gene for a biotechnology-based protein that Regeneron and Amgen Inc. are developing to treat neurological diseases.
The patent also was awarded to the Max Planck Institute, which has licensed the technology exclusively to Regeneron.
Regeneron, a fledgling biotechnology company based in Tarrytown, N. Y., and Amgen hope that the protein--called brain derived neurotrophic factor, or BDNF--can be used to treat Parkinson’s disease, Alzheimer’s disease and other maladies.
Amgen, the Thousand Oaks-based biotechnology giant, also has invested more than $18 million in Regeneron to help finance its research. Regeneron said it plans to begin clinical trials of BDNF in the latter half of this year.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
